Table 1.
Patient characteristics (n = 76)
| Characteristic | n (%) |
|---|---|
| Sex | |
| Male | 42 (55) |
| Female | 34 (45) |
| Age at diagnosis (years), median (range) | 25 (3-61) |
| Site of primary tumor | |
| Lower limb | 51 (67) |
| Upper limb | 8 (12) |
| Head and neck | 6 (8) |
| Trunk | 5 (6.5) |
| Pelvis | 2 (2.5) |
| Other | 3 (4) |
| Stage at diagnosis | |
| Localized/locally advanced | 23 (30) |
| Metastatic | 53 (70) |
| Metastasis-free interval, months, median (range) | 13.4 (1-312) |
| Site of metastasis | |
| Lungs | 71 (93) |
| Brain | 12 (16) |
| Number of metastatic sites, median (range) | 2 (1-5) |
| Any previous surgery | |
| No | 29 (38) |
| Yes | 47 (62) |
| Any previous systemic therapy | |
| No | 17 (22) |
| Yes | 59 (78) |
| Number of previous systemic therapies, median (range) | 1 (0-6) |
| Any previous chemotherapy | |
| No | 55 (72) |
| Yes | 21 (28) |
| Any previous TKI | |
| No | 20 (26) |
| Yes | 56 (74) |
| Previous systemic therapy | |
| Sunitinib | 39 |
| Pazopanib | 26 |
| Anthracycline-based chemotherapy | 13 |
| Crizotinib | 2 |
| Gemcitabine-based | 1 |
| Trabectedin | 1 |
| Oral vinorelbine | 1 |
| Ifosfamide-etoposide | 1 |
| Belinostat-bortezomib | 1 |
TKI, tyrosine kinase inhibitor.